Thrombosis Research

Article	Citations
Direct oral anticoagulants for the treatment of cerebral vein thrombosis	85
Age over 75 does not increase the risk of recurrent venous thromboembolism: Findings from the RIETE registry	76
Deep vein thrombosis in a tertiary hospital from Ethiopia	75
The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry	74
Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza	59
Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in young people with cystic fibrosis	53
Extended-duration thromboprophylaxis following major abdominopelvic surgery – For everyone or selected cases only?	52
Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia	51
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome	50
DOAC drug levels: Does “knowing” lead to safer care?	48
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?	48
Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention	46
PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?	43
Exploration of rotational thromboelastometry (ROTEM) to characterize the coagulation profiles of newly diagnosed pediatric leukemia patients	40
PO-99 Non-traumatic subdural hematoma and occult cancer: a Danish nationwide cohort study	40
Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism	39
Thromboelastometry in daily obstetric practice: At what amount of blood loss do we find abnormal results? A retrospective clinical observational study	38
Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation	36
Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study	35
DOACs: A perfect fit for patients with bariatric surgery?	34
Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats	34
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome	31
Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability	30
Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2	29
Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study	29

Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study	28
External validation of a model to predict women most at risk of postpartum venous thromboembolism: Maternity clot risk	27
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease	27
Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms	27
Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model	26
Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study	26
Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials	26
Osimertinib-related venous thromboembolism in non small lung cancer	25
Opinion and practice survey about the use of prognostic models in acute pulmonary embolism	25
Barriers and facilitators to preventing venous thromboembolism in oncology practice	25
Comparative analysis of Lox-1 and CD36 expression in human platelets and on circulating microparticles during ARDS-induced coagulopathy	24
Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy	24
Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia	24
Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma	24
Corrigendum to “Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation” [Thromb. Res. 229 (2023) 53–68]	23
The effects of an aggressive breast tumor on thrombosis after antithrombin downregulation in a hypercoagulable mouse model	22
Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism	21
Management of venous thromboembolism in pregnancy	21
Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity	21
Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19	21
Evolving data on cardiovascular complications in cancer	20
To clot, or not to clot: The dilemma of hormone treatment options for menopause	20
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice	19
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia	19
Detection of anti-GPIbα autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination	19
Modern imaging of acute pulmonary embolism	19
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine	19
Publisher’s note	19
Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism	18
Efficacy and safety of intra-operative thromboprophylaxis with low-molecular-weight-heparin or heparin in patients undergoing surgical resection of colorectal cancer: A post-hoc analysis of the PERIOP	18
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY	18
Thrombin generation is associated with ischemic stroke at a young age	18
Development and validation of a clinical prediction model for post thrombotic syndrome following anticoagulant therapy for acute deep venous thrombosis	18
Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide Registry	18
Major in-hospital bleeding in patients with pulmonary embolism treated with systemic thrombolysis	17
Crosstalk between hemostasis and immunity in cancer pathogenesis	17
Derivation and external validation of a portable method to identify patients with pulmonary embolism from radiology reports: The READ-PE algorithm	17
Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence	17
Outcomes of isolated distal thrombosis managed with serial compression ultrasonography	17
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability	16
Survival patterns among venous thromboembolism patients with hematologic malignancies in Alberta, Canada from 2003 to 2015	16
Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants: an intervention study in community pharmacies	16
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	16
A novel interaction between extracellular vimentin and fibrinogen in fibrin formation	16
Downregulation of protein S in patients with severe COVID-19 augments the prothrombotic state	16
Quantitative analysis of clot density, fibrin fiber radius, and protofibril packing in acute phase myocardial infarction	16
DOACs for Older adults with Atrial Fibrillation and Falls: Results from the prospective single-centre DOAFF study	16
Association of telomere length and mitochondrial DNA copy number, two biomarkers of biological aging, with the risk of venous thromboembolism	16
COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics	16
WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor	16

Characterization of a canine freeze-dried platelet-derived hemostatic agent: A preclinical model for surgical and traumatic hemorrhage	16
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease	15
Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population	15
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism	15
Low-grade endotoxemia and risk of recurrent thrombosis in primary antiphospholipid syndrome. The multicenter ATHERO-APS study	15
Bivalirudin or heparin for systemic anticoagulation during pediatric extracorporeal membrane oxygenation: Multicenter retrospective study	15
The prognostic value of ORBIT risk score in predicting major bleeding in patients with acute coronary syndrome	15
Effect of sample heat inactivation on test levels of HIT-IgG(PF4-H) detected by the ACL AcuStar	14
Editorial Board	14
Navigating the twilight zone of DOAC plasma monitoring	14
COVID-19 in thrombosis research: An editorial perspective	14
Effect of regular exercise training on platelet function in patients with cardiovascular disease and healthy individuals: A systematic review	14
Editorial Board	14
Incidence and risk factors of venous thrombotic events in pediatric patients with CNS tumors compared with non-CNS cancer: A population-based cohort study	14
Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies	14
Effect of α2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism	14
A response to a letter to the editor TR-D-22-00887	14
Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers	14
Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors	14
Estimating the measurement uncertainties of the international sensitivity index of 12 thromboplastins through Monte Carlo simulation	14
An international survey of low molecular weight heparin prescribing in the context of antenatal venous thromboembolism	14
Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death	14
Cerebral venous thrombosis: A rare complication of Ramsay Hunt syndrome (case report and literature review)	13
A retrospective study of the role of preoperative ultrasonography in the detection of deep vein thrombosis in 1750 patients with gastric and colorectal cancers	13
Increased platelet glycoprotein IIb/IIIa activation precedes continuous-flow left ventricular assist device pump thrombosis events	13
Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study	13
Health care professionals' conceptions of respiratory symptoms and physical activity in patients with acute pulmonary embolism. A phenomenographic interview study.	13
Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome	13
Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer	13
Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis	13
Editorial Board	13
Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: Impact on plasma drug levels	13
Initiation of anticoagulation in atrial fibrillation by primary care physicians: Results of a telephone survey	12
PO-11 Venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study	12
PO-41 Paraneoplastic deep vein thrombosis in pre-existing full-dose anticoagulation with dabigatran: a case report	12
PO-58 Venous and arterial tromboembolic events among hospitalized cancer patients with SARS-COV2 infection	12
PO-48: Coagulopathy in multiple myeloma	12
PO-102 Bleeding management challenges in rare cancer-associated thrombosis: a case report of inferior vena cava thrombus in a patient with testicular germ cell tumour	12
Editorial Board	12
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial	12
PO-20 Incidence of venous thromboembolism in men with prostate cancer and men without prostate cancer: a nationwide population-based cohort study in Sweden	12
PO-52 Immunophenotypic analysis of haematological malignancies in a Pakistani population: a step towards formulation of hospital cancer registry	12
PO-62 Tinzaparin: anti-cancer properties?	12
PO-13 Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study (STAC)	12
PO-08 Cancer outpatients under thromboprophylaxis: an analysis of choices and events	12
Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients	12
OC-04 Incidence, predictors and clinical outcomes of venous thromboembolism in patients with newly diagnosed pancreatic ductal adenocarcinoma: results of the prospective BACAP-VTE study	12
PO-21 Incidence of venous thromboembolism events in outpatients with cancer and COVID-19.	12
Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A	12
PO-46: Perception of the risk of thrombosis in clinicians treating patients with multiple myeloma	12
PO-105 Quantification of citrullinated histones in human blood samples: challenges and development of a nucleosome-based assay to quantify H3Cit-DNA in human plasma	12
OC-13 A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts	12
PO-35: A method for prioritisation and translation of pleiotropic effects into clinical applications: lessons from low molecular weight heparin treatment in cancer	11
PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery	11
PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients	11
“COVID-19 associated divergent thrombotic thrombocytopenic purpura (TTP) syndromes reported so far, five and counting”: Classification and possible therapeutic options	11
Editorial Board	11
Right ventricular pressure overload related to residual thrombotic burden in patients 1 year after acute pulmonary embolism: From the Nagoya PE study	11
PO-14: Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients	11
PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms	11
Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes	11
Venous and arterial thromboembolism with immunotherapy compared to platinum-based therapy	11
Circulating immune cells with megakaryocyte signature in response to COVID-19 mRNA vaccination	11
Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting	11
Challenging clinical scenarios for therapeutic anticoagulation: A practical approach	11
PO-50: Molecular landscape of the coagulome of oral squamous cell carcinoma	11
Optimizing antithrombotic therapy for atrial fibrillation in cancer	11
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project	11
Editorial Board	11
Vaccine-associated thrombocytopenia	11
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials	10
Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination	10
Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: A comprehensive assessment	10
Long term recovery of right ventricular function after treatment of intermediate and high risk pulmonary emboli	10
Copyright	10
Editorial Board	10
Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study	10
Implications of bleeding on subsequent cardiovascular events in patients with atrial fibrillation after acute coronary syndrome or PCI	10
Cancer-associated splanchnic vein thrombosis: Clinical features upon diagnosis and short-term outcomes	10
Bleeding outcomes and management of supratherapeutic episodes secondary to warfarin in children: A single center 10-year experience	10

Whole exome sequencing identifies genetic variants in Chinese Han pregnant women with venous thromboembolism	10
Letter to the Editor Re “Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion”	10
OC-09: Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial	10
A novel role of acellular hemoglobin in hemolytic thrombosis	10
Venous thromboembolism risk assessment scale for prediction of venous thromboembolism in inpatients with cancer: A meta-analysis	10
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors	10
Hemostatic status in women with breast cancer and cardiotoxicity associated to doxorubicin-based chemotherapy – A one-year follow-up study	10
OC-12: Stroke and risk of cancer: a Danish population-based cohort study	10
Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study	10
The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?	9
Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis	9
Positive predictive value and sensitivity of cancer-associated venous thromboembolism diagnoses in the Danish National Patient Register	9
Being John Plasma Volumovich, pecularities of plasma volume estimation in patients with polycythemia vera	9
Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention.	9
Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis	9
Regulation of fibrinogen synthesis	9
Prothrombotic genotypes and risk of venous thromboembolism in occult cancer	9
Accuracy of transthoracic lung ultrasound for diagnosing pulmonary embolism: An updated systematic review and meta-analysis	9
Antithrombin testing and treatment in pregnancy: Their real-world relationship to clinical outcomes	9
Mechanical thrombectomy vs catheter directed thrombolysis vs anticoagulation alone: A tertiary center PERT Registry Cohort Analysis	9
Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis	9
The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective	9
Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies	9
High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study	9
Clinical and endoscopic findings in patients with acute gastrointestinal bleeding associated with direct oral anticoagulants: Results from a single-center prospective cohort study	9
Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension	9
The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants	9
The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer	9
Predictors of cancer in patients with acute pulmonary embolism	9
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	9
Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients	9
Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated pro	9
Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia	9
Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis	9
Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE)	9
Endothelial dysfunction, a predictor of cardiovascular disease in HIV patients on antiretroviral therapy: A systematic review and meta-analysis	8
Strategies for improving guideline adherence of anticoagulants for patients with atrial fibrillation in primary healthcare: A systematic review	8
Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer	8
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients	8
Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management	8
F9 mRNA splicing aberration due to a deep Intronic structural variation in a patient with moderate hemophilia B	8
Not all patent foramen ovales are alike!	8
Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study	8
Inhibitory effects of resveratrol on platelet activation and thrombosis in colon cancer through regulation of the MAPK and cGMP/VASP pathways	8
Scoping review of current evidence on the incidence of Venous thromboembolism (VTE) in the East Asian population	8
NLRP3 inflammasome contributes to endotoxin-induced coagulation	8
Adhesive properties of plasma-circulating and platelet-derived microvesicles from healthy individuals	8
Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis	8
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection	8
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	8
Effect of blood loss during caesarean section on coagulation parameters	8
Comparison of important factors to patients recovering from pulmonary embolism and items covered in patient-reported outcome measures: A mixed-methods systematic review	8
Elevated von Willebrand factor levels in multiple myeloma: dysregulated mechanisms of both secretion and clearance	8
Breaking down tumor thrombus: Current strategies for medical management	8
Development of an ADAMTS13-based Therapy for Thrombosis	8
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban	8
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway	8
COVID-19 and thrombosis: The role of hemodynamics	8
Novel CT-derived parameter is associated with low cardiac index in acute pulmonary embolism	8
OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants	8
Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study	8
PO-88 Validation and comparison of the Protecht, Conko, and Khorana score for prediction of venous thromboembolism in ambulatory cancer patients: a retrospective cohort study	8
Depression and anxiety up to two years after acute pulmonary embolism: Prevalence and predictors	8
Unveiling the predictive capacity of inflammatory and platelet markers for central retinal artery occlusion	8
Comparative effectiveness among thromboprophylaxis strategies after the Fontan operation: A systematic review and network meta-analysis	7
Knowledge about atrial fibrillation and anticoagulation affects the risk of clinical outcomes	7
Corrigendum to “Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients” [Thromb. Res. 186 2020. 80–85]	7
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients	7
Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran	7
Letter in response to a recent article by Zhang et al.[]	7
Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients	7
Links between thrombosis and inflammation in traumatic brain injury	7
Coagulation profile in newly diagnosed T-cell acute lymphoblastic leukemia	7
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study	7
Assessing in-hospital cardiovascular, thrombotic and bleeding outcomes in patients with chronic liver disease undergoing left ventricular assist device implantation	7
Inferior vena cava contrast reflux grade is associated with a reduced cardiac index in acute pulmonary embolism	7
Von Willebrand factor in aortic or mitral valve stenosis and bleeding after heart valve surgery	7
Obesity: Effects on bone marrow homeostasis and platelet activation	7
Machine learning model for predicting physical activity related bleeding risk in Chinese boys with haemophilia A	7
Protein S deficiency caused by cryptic splicing due to the novel intron variant c.346+5G>C in PROS1	7
Venous thromboembolism after fast-track elective revision hip and knee arthroplasty – A multicentre cohort study of 2814 unselected consecutive procedures	7
Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy	7
Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia	7
Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation	7
Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply ‘hyperfibrinolysis’	7
Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation	7
Arthropathy in people with mild haemophilia: Exploring risk factors	7
Diagnostic accuracy of four different D-dimer assays: A post-hoc analysis of the YEARS study	7
Complications associated to midline- and long peripheral catheters in adults. Systematic review of literature and proposal for a standardized model for data collection	7
Cancer-associated venous thromboembolism in the direct oral anticoagulants era: Insight from the COMMAND VTE Registry-2	7
The impact of warfarin on overall survival in cancer patients	7
Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study	7
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia	7
Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism	7
Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation	7